Accepted for Publication: December 25, 2021.
Published Online: January 28, 2022. doi:10.1001/jamainternmed.2021.8538
Corresponding Author: Adriana M. Hung, MD, MPH, Tennessee Valley Healthcare System, Division of Nephrology and Hypertension, Vanderbilt University, 1611 21st Ave S, S3223 MCN, Nashville, TN 37232 (email@example.com).
Author Contributions: Adriana Hung, Otis Wilson, Zhihong Yu, and Hua Chang Chen had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Design and conduct of the study: All Authors
Collection, management, analysis, and interpretation of the data: Hung, Siew, Wilson, Zhihong Yu, Hua Chang Chen,
Drafting the manuscript: Adriana M. Hung, Siew, Bick, Tuteja, Hunt.
Critical revision of the manuscript for important intellectual content: All authors
Statistical Analysis: Zhihong Yu, Ran Tao, Hua Chang Chen, Robert A. Greevy
Decision to submit the manuscript for publication: All Authors.
Statistical analysis: Hung, Yu, Chen, Wendt, Wilson, Greevy, Akwo, Zhou, Iyengar, Robinson-Cohen, Tao.
Obtained funding: Hung, Gaziano, Chang.
Administrative, technical, or material support: Hunt, Ho, Huffman, Chang, Cho, Susztak, Robinson-Cohen, Tuteja.
Supervision: Hung, Polimanti, Gaziano, Luoh, Casas.
Conflict of Interest Disclosures: Dr Hung reports grants from Veterans Health CSR&D Merit Grant CX001897 and grants from Veterans Health MVP035 MVP COVID-19 Science Program during the conduct of the study; grants from Vertex Pharmaceutical outside the submitted work. Dr Bick reports personal fees from TenSixteen Bio outside the submitted work. Dr Hunt reports other from Akebia Therapeutics, Inc. Safety adjudication in COVID-19 clinical trial during the conduct of the study. Dr Wendt reports grants from NIMH outside the submitted work. Dr Akwo reports grants from American Heart Association Postdoc Award #20POST35210952/Akwo/2020 during the conduct of the study. Christopher J O'Donnell: Dr O'Donnell reports income from Novartis Institute for Biomedical Research as a salaried employee outside the submitted work. Dr Susztak reports grants from GSK, Regeneron, Bayer, BiPI, Novo Nordisk, Maze, Novartis, Gilead and other from AZ, Pfizer, Bayer, GSK Consulting outside the submitted work. Dr Siew reports grants from Veterans Health Services Research and Development Grant SDR 18-194 Million Veteran Program Gamma Program during the conduct of the study; personal fees from Akebia Therapeutics, Inc. Consultant on and personal fees from Da Vita, Inc. Honorarium for an invited educational talk on AKI epidemiology at the Da Vita Annual Physician Leadership Conference outside the submitted work; and Serves on the editorial board for the Clinical Journal of the American Society of Nephrology; and has received royalties as an author for UptoDate.
Funding/Support: This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award #MVP035 (MVP COVID-19 Science Program) and VA Clinical Science Research and Development-investigator grant CX001897 (Dr Hung) Genetic of Kidney Disease and Hypertension-Risk Prediction and Drug Response in the MVP. Drs Siew’s and Matheny’s time was covered by grant HX002489 (Drs Siew and Matheny).
Role of the Funder/Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: A complete list of investigators and staff in the the VA Million Veteran Program COVID-19 Science Initiative is provided in Supplement 2.
Disclaimer: This publication does not represent the views of the Department of Veteran Affairs or the United States Government.
Data Sharing Statement: The protocol, statistical code, are available from Dr Hung. However, data will require approval from the Office of Research Development and the Million Veteran Program.
Additional Contributions: We thank the MVP leadership and MVP COVID-19 Science Program. The MVP COVID-19 Science Initiative core acknowledgment and the MVP program core acknowledgment are included in eTable 9 in Supplement 1.
B , Cai
M , Xie
Y , Gibson
AK , Maddukuri
G , Al-Aly
Z . Acute kidney injury in a national cohort of hospitalized US veterans with COVID-19. Clin J Am Soc Nephrol
. 2020;16(1):14-25. doi:10.2215/CJN.09610620
MS , Freedman
BI , Langefeld
et al; SK Investigators. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int
. 2013;83(1):114-120. doi:10.1038/ki.2012.263
KE , Deppen
SA , DuVall
et al. Incrementally transforming electronic medical records into the observational medical outcomes partnership common data model: a multidimensional quality assurance approach. Appl Clin Inform
. 2019;10(5):794-803. doi:10.1055/s-0039-1697598
E , Altman
DG , Egger
M , Pocock
SJ , Gøtzsche
PC , Vandenbroucke
JP ; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ
. 2007;335(7624):806-808. doi:10.1136/bmj.39335.541782.AD
SS , Wald
R , Chertow
et al. Validity of International Classification of Diseases, Ninth Revision, Clinical modification codes for acute renal failure. J Am Soc Nephrol
. 2006;17(6):1688-1694. doi:10.1681/ASN.2006010073
Jr , Yoon
JS , Rentsch
et al. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index. PLoS One
. 2020;15(11):e0241825. doi:10.1371/journal.pone.0241825
MG , Bruce
SL , Slater
et al. Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series. BMJ
. 2020;369:m1996. doi:10.1136/bmj.m1996
GM , Blasio
A , Donovan
et al. Recessive, gain-of-function toxicity in an APOL1
BAC transgenic mouse model mirrors human APOL1
kidney disease. Dis Model Mech
. 2021;14(8):14. doi:10.1242/dmm.048952
OA , Zhang
JY , VerPlank
et al. APOL1
kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases. Proc Natl Acad Sci USA
. 2016;113(4):830-837. doi:10.1073/pnas.1522913113